Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

NAV as on 25-04-2025

₹ 32.51

1.2%

1D

Inception Returns

22.9%

/yr

Historical NAV & Returns

Absolute

zero opening, trading, fund transfer fee
977 people have invested ₹ 35.5L in Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth in the last three months

About Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is an equity fund. This fund was started on 11 July, 2019. The fund is managed by Dhaval Shah. The fund could potentially beat inflation in the long-run.

Key Parameters

  1. Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has ₹815 Cr worth of assets under management (AUM) as on Mar 2025 and is less than category average.
  2. The fund has an expense ratio 1.1.

Returns

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has given a CAGR return of 22.85% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 18.49%, 20.05% and 21.94% respectively.

Holdings

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials. Its top holdings are Sun Pharmaceuticals Industries Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Apollo Hospitals Enterprise Ltd, Abbott India Ltd

Taxation

As it is a sector - healthcare mutual fund the taxation is as follows:
For short term (less than a year) capital gains will be taxed at 20%
For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefit
Dividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.

Investment objective of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.

Minimum Investment and lockin period

Minimum investment for lump sum payment is INR 1000.00 and for SIP is INR 100.00. Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has no lock in period.

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Overview

Expense ratio1.06%
Benchmark
BSE Healthcare TR INR
AUM₹815 Cr
Inception Date11 July, 2019
Min Lumpsum/SIP₹1000/₹100
Exit Load
1.0%
Lock InNo Lock-in
TurnOver
33.35%
STCGSelling mutual fund before 1 year, returns taxed at 20%.
LTCGAfter 1 year, 12.5% tax on returns over ₹1.25 lakh/year.
Risk
Risk meter
pointer
Very High Risk

INDmoney Rank for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Powered by IND quant engine
IND ranking is not available for this fund.
img
Beats FD returns for both 3Y & 5Y duration
img
5Y returns in the bottom 25% of the category
img
3Y returns in the bottom 25% of the category

Trailing Returns

as on (25-Apr-25)

Period
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Nifty 500
sector - healthcare
1M
1.7%
4.5%
1.4%
3M
-0.4%
3.2%
-1.6%
6M
-2.2%
-2.6%
-1.1%
1Y
18.5%
7.7%
21.8%
3Y
20%
14.3%
19.6%
5Y
21.9%
23.9%
22.6%

Fund Distribution

as on (31-Mar-25)

  • Equity 98.8%

  • Debt & Cash 1.2%

Mid cap
44.1%

Large cap
31.5%

Small cap
23.2%

Sector Allocation

Mar'25

Feb'25

Jan'25

Dec'24

Nov'24

Oct'24

Sep'24

Health
99.2%
Basic Materials
0.8%
All changes are between Jan'25 and Mar'25
Mar'25
Feb'25
Jan'25
Fund Returns
7.45%
-7.34%
-7.64%
Nifty 500
7.25%
-7.88%
-4.01%
  • This fund’s returns stands at 7.45% whereas the fund’s underlying benchmark Nifty 500 returns stands at 7.25% as on Mar'25
  • This fund outperformed Nifty 500 by 0.20% in Mar'25
Parameters
Mar'25
Feb'25
Jan'25
AUM
₹ 814.9 Cr
₹ 754.8 Cr
₹ 815.1 Cr
  • AUM of the fund stands at 814.9 Cr as of Mar'25
  • AUM increased by 60.2 Cr between Mar'25 and Feb'25
Top Stocks bought last month
Apollo Hospitals Enterprise Ltd's allocation increased from 5.93% to 6.9%
Apollo Hospitals Enterprise Ltd's allocation increased from 5.93% to 6.9%
Sanofi India Ltd's allocation increased from 1.1% to 1.62%
Sanofi India Ltd's allocation increased from 1.1% to 1.62%
Alembic Pharmaceuticals Ltd's allocation increased from 2.37% to 2.74%
Alembic Pharmaceuticals Ltd's allocation increased from 2.37% to 2.74%
Top Stocks sold last month
Cipla Ltd's allocation decreased from 8.9 % to 8.44 %
Cipla Ltd's allocation decreased from 8.9 % to 8.44 %
Torrent Pharmaceuticals Ltd's allocation decreased from 7.6 % to 7.05 %
Torrent Pharmaceuticals Ltd's allocation decreased from 7.6 % to 7.05 %
Abbott India Ltd's allocation decreased from 6.56 % to 6.14 %
Abbott India Ltd's allocation decreased from 6.56 % to 6.14 %
Cash allocation has gone down from 1.4% to 1.2%
Cash allocation has gone down from 1.4% to 1.2%

Top 2 Sectors in March were Health, Basic Materials

Mar'25
Health
99%
Basic Materials
Feb'25
Health
99%
Basic Materials
  • Equity

  • Returns %

  • Fund Ratios

  • Overview

Funds
1Y Returns
3Y Returns
5Y Returns
Since Inception
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
18.49%
20.05%
21.94%
22.85%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth
25.47%
25.13%
26.81%
22.86%
SBI Healthcare Opportunities Fund Direct Growth
SBI Healthcare Opportunities Fund Direct Growth
25.35%
24.98%
26.68%
18.44%
LIC MF Healthcare Fund Direct Growth
LIC MF Healthcare Fund Direct Growth
22.27%
17.85%
19.59%
20.34%
  • Gainers

  • Losers

Fund
Mar'25
Feb'25
Jan'25
No of Holdings
30
29
28
Top 5 Company Concentration
43.1%
43.5%
43.6%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (14.6%)
Sun Pharmaceuticals Industries Ltd (14.5%)
Sun Pharmaceuticals Industries Ltd (14.7%)
No of Sectors
2
2
2
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (99.2%)
Health (99.2%)
Health (99.2%)
Loading...
We are taking more time than usual
Dhaval Shah
Dhaval Shah
Fund Manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth, since 11 July 2019
Top funds managed
Fund House
Aditya Birla Sun Life AMC Ltd
Total AUM
₹3.68L Cr
as on 31-Mar-2025
Address
Aditya Birla Sun Life AMC Ltd,One World Centre, Tower 1, 17th Floor,Jupiter Mill Compound, 841, Senapati Bapat Marg,Elphinstone Road
Phone
+912243568000
Website
connect@birlasunlife.com

Mutual Fund Insights

Insights icon
In the last 3 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 25.13% return, outperforming this fund by 5.08% per annum.
Insights icon
Over the last 3 months, this fund has increased expense ratio by 14.0% moving from 0.93 to 1.06.
Insights icon
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 1.06% which is lower than the category average expense ratio of 1.41%.
Insights icon
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 26.81% return, outperforming this fund by 4.87% per annum.
Insights icon
Over the last 3 months, this fund has experienced a 8.5% drop in AUM moving from 890.33 Cr to 814.95 Cr.
Insights icon
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 33.77% return, outperforming this fund by 15.28%.

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Highlights

Risk meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
About the fund

About the fund

This fund has delivered an average annual returns of 22.85% since inception which is more than its category average return of 17.91%
Fund Allocations

Fund Allocations

This fund has an allocation of 98.79% in Equity, 0% in Debt and 1.21% in Cash related instruments
AUM size ₹815 Cr

AUM size ₹815 Cr

This fund has AUM of ₹815 Cr which is less than its category average of ₹ 1821 Cr
Expense Ratio 1.06%

Expense Ratio 1.06%

This fund has an expense ratio of 1.06% which is less than its category average expense ratio of 1.44%
Most Popular Comparisons
    • Aditya Birla Sun Life Pharma & Healthcare Fund
      Aditya Birla Sun Life Pharma & Healthcare Fund
      Vs
    • Nippon India Pharma Fund Direct Growth
      Nippon India Pharma Fund Direct Growth
    Compare
    • Aditya Birla Sun Life Pharma & Healthcare Fund
      Aditya Birla Sun Life Pharma & Healthcare Fund
      Vs
    • ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
      ICICI Prudential Pharma Healthcare and Diagnostics P.H.D Fund Direct Growth
    Compare
    • Aditya Birla Sun Life Pharma & Healthcare Fund
      Aditya Birla Sun Life Pharma & Healthcare Fund
      Vs
    • SBI Healthcare Opportunities Fund Direct Growth
      SBI Healthcare Opportunities Fund Direct Growth
    Compare
    • Aditya Birla Sun Life Pharma & Healthcare Fund
      Aditya Birla Sun Life Pharma & Healthcare Fund
      Vs
    • DSP Healthcare Fund Direct Growth
      DSP Healthcare Fund Direct Growth
    Compare
    • Aditya Birla Sun Life Pharma & Healthcare Fund
      Aditya Birla Sun Life Pharma & Healthcare Fund
      Vs
    • LIC MF Healthcare Fund Direct Growth
      LIC MF Healthcare Fund Direct Growth
    Compare

Frequently Asked Questions for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

The current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is ₹32.51 as on 25-Apr-2025.
Existing (Absolute + CAGR) as on 25-Apr-2025.
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
Absolute Returns
CAGR Returns
1 Month Returns
1.72%
1.72%
6 Month Returns
-2.22%
-2.22%
1 Year Returns
18.49%
18.49%
3 Years Returns
73%
20.05%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
1.06% as on March 2025
₹815 Cr as on March 2025
Sun Pharmaceuticals Industries Ltd(14.61%), Cipla Ltd(8.44%), Torrent Pharmaceuticals Ltd(7.05%), Apollo Hospitals Enterprise Ltd(6.9%), Abbott India Ltd(6.14%) as on March 2025
The alpha ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
-4.9
-0.56
-0.55
As on March 2025
The alpha for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated against BSE Healthcare TR INR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
0.96
0.96
0.92
As on March 2025
The Beta for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
0.36
0.74
1.05
As on March 2025
The sharpe ratio for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is calculated with BSE Healthcare TR INR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
19.8
16.88
18.82
As on March 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.31 as on March 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Dhaval Shah is the fund manager of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth
The Exit load of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is 1%